Akeso Starts Phase III Cadonilimab Study in Resectable Colon Cancer Akeso began dosing in COMPASSION-40, a Phase III study of cadonilimab around...

https://www.narrowit.com/news/akeso-starts-phase-three-cadonilimab-colon-cancer-study-2026-10-10
#Akeso #Cadonilimab #PhaseIiiTrial #ColonCancer